ライフサイエンスコーパス: cyclooxygenase-2 inhibitor

1 and this induction could be antagonized by a cyclooxygenase-2 inhibitor.

2 d be decreased by treatment with a selective cyclooxygenase-2 inhibitor.

3 ncreased cardiovascular risk associated with cyclooxygenase-2 inhibitors.

4 astrointestinal safety outcomes of selective cyclooxygenase-2 inhibitors.

5 retinoids, statins, and tyrosine kinase and cyclooxygenase-2 inhibitors.

6 These effects were suppressed by a cyclooxygenase-2 inhibitor, a drug type known to reduce

7 emity edema, and hypertension indicates that cyclooxygenase-2 inhibitors affect the kidney in a manne

8 Wild-type mice or human volunteers taking cyclooxygenase-2 inhibitors also showed increased plasma

9 onstatin cholesterol-lowering medications or cyclooxygenase 2 inhibitors and the development of TAO.

10 ogy; however, simultaneous administration of cyclooxygenase-2 inhibitors and dietary hen egg-white ly

11 uding newer N-methyl-D-asparate antagonists, cyclooxygenase-2 inhibitors and membrane stabilizing ana

12 ing other agents with NSAID-like mechanisms (cyclooxygenase-2 inhibitors and salicylates).

13 Newly developed drugs, such as selective cyclooxygenase-2 inhibitors and soluble tumor necrosis f

14 provided evidence that aspirin, celecoxib, (cyclooxygenase-2 inhibitor), and statins (3-hydroxy-3-me

15 atins, nonsteroidal anti-inflammatory drugs, cyclooxygenase-2 inhibitors, and aspirin on colorectal c

16 ased risk associated with the use of certain cyclooxygenase-2 inhibitors, and randomized trial data s

17 The anticancer effects of bisphosphonates, cyclooxygenase-2 inhibitors, and statins may expand thei

18 f the anticancer effects of bisphosphonates, cyclooxygenase-2 inhibitors, and statins, may lead to th

19 r events has been demonstrated with multiple cyclooxygenase-2 inhibitors, and this increased risk has

20 Selective cyclooxygenase-2 inhibitors are as effective as nonselec

21 The European Medicines Agency concluded that cyclooxygenase-2 inhibitors are contraindicated in patie

22 oidal anti-inflammatory drugs) and selective cyclooxygenase-2 inhibitors are generating interest beca

23 However, these new selective cyclooxygenase-2 inhibitors are not risk free, and care

24 Cyclooxygenase-2 inhibitors are potent anti-inflammatory

25 L-4 since treating UV-irradiated mice with a cyclooxygenase-2 inhibitor blocked its production.

26 A specific cyclooxygenase-2 inhibitor blocked the formation of thre

27 phages with indomethacin, a cyclooxygenase-1/cyclooxygenase-2 inhibitor, blocked PGE(2) production.

28 For example, selective cyclooxygenase-2 inhibitors can provide the same symptom

29 A recent study showing that celecoxib, a cyclooxygenase-2 inhibitor, can alter the natural histor

30 reliminary data suggested that the selective cyclooxygenase -2 inhibitor celecoxib (CBX) might enhanc

31 e antidepressant properties of the selective cyclooxygenase 2 inhibitor celecoxib (SMD, -0.29; 95% CI

32 Treatment with a cyclooxygenase 2 inhibitor celecoxib significantly impro

33 tion with arachidonic acid and the selective cyclooxygenase-2 inhibitor celecoxib.

34 1 (MUC1)-based vaccine in combination with a cyclooxygenase-2 inhibitor (celecoxib), and low-dose che

35 Treatment with a selective cyclooxygenase-2 inhibitor, celecoxib, markedly inhibite

36 linical cancer prevention studies by using a cyclooxygenase-2 inhibitor, celecoxib.

37 d gliosis were assessed in pups treated with cyclooxygenase-2 inhibitor compared to controls at Day 1

38 increased risk associated with a variety of cyclooxygenase-2 inhibitors compared with either a tradi

39 roidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors consistently reduce postoper

40 iovascular risks of treatment with selective cyclooxygenase 2 inhibitors (coxibs) and nonselective no

41 ular risks associated with anti-inflammatory cyclooxygenase 2 inhibitors (coxibs) by targeting the pr

42 Cyclooxygenase-2 inhibitors (coxibs) are characterized b

43 Over the past five years, selective cyclooxygenase-2 inhibitors (coxibs) have accounted for

44 Although cyclooxygenase-2 inhibitors (coxibs) were developed to c

45 ted to an 'imbalance theory' suggesting that cyclooxygenase-2 inhibitors create an 'imbalance' betwee

46 Lumiracoxib is a selective cyclooxygenase-2 inhibitor developed for the symptomatic

47 Cardiovascular side effects associated with cyclooxygenase-2 inhibitor drugs dominate clinical conce

48 tudies indicated that celecoxib, a selective cyclooxygenase-2 inhibitor, exhibits potent antitumor ac

49 may be an important alternative to selective cyclooxygenase-2 inhibitors for patients who need aspiri

50 epidermal growth factor receptor inhibitors, cyclooxygenase-2 inhibitors, green tea extract, and pero

51 t concentrations (1-2 microM) of a selective cyclooxygenase-2 inhibitor had no detectable, direct eff

52 ds, non-steriodal antiinflammatory drugs and cyclooxygenase-2 inhibitors have been shown not to impac

53 ors for a nonselective NSAID and a selective cyclooxygenase 2 inhibitor in a double-blind outcomes tr

54 d clarify the true benefits of perioperative cyclooxygenase-2 inhibitors in acute pain management str

55 y justification for using the more expensive cyclooxygenase-2 inhibitors in preference to nonsteroida

56 tion of epidermal growth factor receptor and cyclooxygenase-2 inhibitors in SCCHN is warranted.

57 controversy surrounding the proper place of cyclooxygenase-2 inhibitors in the hierarchy of treatmen

58 udies have demonstrated an important role of cyclooxygenase-2 inhibitors in the management of acute p

59 increased myocardial infarction with certain cyclooxygenase-2 inhibitors, in particular rofecoxib.

60 studies, one may conclude that perioperative cyclooxygenase-2 inhibitors, in standard doses, decrease

61 The data comparing the cyclooxygenase-2 inhibitors is difficult to interpret be

62 -daily treatment with 400 mg of celecoxib, a cyclooxygenase-2 inhibitor, leads to a significant reduc

63 tamin D, other 5-alpha-reductase inhibitors, cyclooxygenase-2 inhibitors, lycopene, and green tea.

64 demiologic and molecular evidence also makes cyclooxygenase-2 inhibitors, lycopene, soy, and green te

65 Cyclooxygenase-2 inhibitors may also reduce colorectal p

66 Concerns have been raised that cyclooxygenase-2 inhibitors may increase thrombotic card

67 Rofecoxib, but perhaps not all cyclooxygenase-2 inhibitors, may be associated with incr

68 that target enzymes in the cascade, such as cyclooxygenase 2 inhibitors, might be candidate treatmen

69 ith dysplastic Barrett's esophagus by use of cyclooxygenase 2 inhibitors, nonsteroidal anti-inflammat

70 In previous work, the cyclooxygenase-2 inhibitor NS-398 inhibited interleukin

71 pression and activity and was blocked by the cyclooxygenase-2 inhibitors NS-398 and Resveratrol.

72 t of cAMP were inhibited only by a selective cyclooxygenase-2 inhibitor, NS-398.

73 The cyclooxygenase-2 inhibitor NS398 blocked PPARgamma-induc

74 or 30 mg/kg (high dose) of a known selective cyclooxygenase-2 inhibitor (NS398).

75 studied the effect of celecoxib, a selective cyclooxygenase-2 inhibitor, on colorectal polyps in pati

76 prescription NSAIDs, particularly selective cyclooxygenase 2 inhibitors (OR = 0.38, 95% CI: 0.25, 0.

77 e treated with either rofecoxib (a selective cyclooxygenase-2 inhibitor) or indomethacin (a non-selec

78 Cyclooxygenase-2 inhibitors, or coxibs, designed to prov

79 (1 mg/kg intraperitoneally) or the selective cyclooxygenase-2 inhibitor parecoxib (20 mg/kg intraperi

80 In contrast, the cyclooxygenase-2 inhibitor parecoxib did not affect the

81 The potential thrombogenic risk of cyclooxygenase-2 inhibitors remains controversial, and c

82 reverse order; aspirin two hours before the cyclooxygenase-2 inhibitor rofecoxib (25 mg every mornin

83 is antiapoptotic effect was inhibited by the cyclooxygenase-2 inhibitor rofecoxib and was restored by

84 a protective strategy such as the selective cyclooxygenase 2 inhibitor, rofecoxib, to avert a clinic

85 of 4T1-tumor-bearing wild-type mice with the cyclooxygenase 2 inhibitor, SC58236, delays primary tumo

86 exposure and chemoprevention, possibly with cyclooxygenase 2 inhibitors, should reduce the incidence

87 us to demonstrate that pain was blocked by a cyclooxygenase-2 inhibitor, suggesting an indirect effec

88 roidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors that block prostanoid synthe

89 ho initiated nonselective NSAID or selective cyclooxygenase 2 inhibitor therapy between January 1, 19

90 -year nonvertebral fracture risk, a study of cyclooxygenase 2 inhibitors versus nonselective nonstero

91 e of nonsteroidal anti-inflammatory drug and cyclooxygenase-2 inhibitor was associated with a reduced

92 Prolonged use of cyclooxygenase-2 inhibitors was minimal, but for those r

93 A novel class of NSAIDs, cyclooxygenase-2 inhibitors, was introduced in 1999.

94 Selective cyclooxygenase-2 inhibitors were developed to reduce the

95 This is exemplified by the clinical use of cyclooxygenase 2 inhibitors, which interfere with PGE2 s

96 emotherapeutic agents suggest that combining cyclooxygenase-2 inhibitors with other agents may have s

97 al studies combining antiangiogenic drugs or cyclooxygenase-2 inhibitors with PDT show improved treat

98 multimodal techniques, for example combining cyclooxygenase-2 inhibitors with regional blocks, may he

99 findings led to the development of selective cyclooxygenase-2 inhibitors, with comparable anti-inflam